Hutchmed (China) Limited HUTCHMED to Announce 2021 Final Results (7818A)
07 Février 2022 - 9:29AM
UK Regulatory
TIDMHCM
RNS Number : 7818A
Hutchmed (China) Limited
07 February 2022
HUTCHMED to Announce 2021 Final Results
Hong Kong, Shanghai & Florham Park, NJ - Monday, February 7,
2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
SEHK:13) will be announcing its final results for the year ended
December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern
Standard Time (EST) / 12:00 noon Greenwich Mean Time (GMT) / 8:00
pm Hong Kong Time (HKT).
Analysts and investors are invited to join a conference call and
audio webcast presentation with Q&A, conducted by HUTCHMED
management.
The conference call and audio webcast will take place at 8:00 am
EST / 1:00 pm GMT / 9:00 pm HKT on Thursday, March 3, 2022 and will
be webcast live via the company website at www.hutch-med.com/event/
. The presentation will be available for downloading before the
conference call begins. Details of the conference call dial-in will
be provided in the financial results announcement and on the
company website. A replay will also be available on the website
shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has more than 4,600 personnel across all
its companies, at the center of which is a team of about 1,500 in
oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch--med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 97 83 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFZGGZFDFGZZM
(END) Dow Jones Newswires
February 07, 2022 03:29 ET (08:29 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024